Filtered By:
Drug: Xolair
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 1700 results found since Jan 2013.
B Lineage Cells and IgE in Allergic Rhinitis and CRSwNP and the Role of Omalizumab Treatment
CONCLUSION: This review highlights current knowledge of the roles of B cells and IgE in the pathogenesis of AR and CRSwNP and a small comparison between the 2 diseases. More systemic studies should be done to elevate the understanding of these diseases and their treatment.PMID:36848269 | DOI:10.1177/19458924221147770
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Junqin Bai Bruce K Tan Source Type: research
Efficacy of biologic therapy on airway hyperresponsiveness in asthma
Ann Allergy Asthma Immunol. 2023 Feb 23:S1081-1206(23)00121-7. doi: 10.1016/j.anai.2023.02.016. Online ahead of print.ABSTRACTAirway hyperresponsiveness (AHR) refers to an exaggerated bronchial constrictor response to a given exogenous inhaled agent and is governed by airway smooth muscle along with mucosal inflammation in asthma. In recent years, the advent of biologics and anti-alarmins have transformed severe asthma treatment in terms of reducing oral corticosteroid-requiring exacerbations and improving disease control, asthma quality of life and spirometry measured lung function. In contrast, there have comparatively b...
Source: Annals of Allergy, Asthma and Immunology - February 25, 2023 Category: Allergy & Immunology Authors: Rory Chan Brian Lipworth Source Type: research
Diagnosis and management of urticaria in Indian settings: Skin allergy research society & #39;s guideline-2022
The objective of this consensus statement is to summarize the updates and provide concise information, including classification, diagnosis, and management of urticaria. Understanding and elimination of the underlying eliciting trigger are essential in all possible cases. The goal of pharmacological treatment is to provide symptomatic relief. Second-generation nonsedating H1 antihistamine continue to be recommended as the first-line treatment, the dose of which can be increased up to four times in patients not responding satisfactorily, in the second step. The role of omalizumab, cyclosporine, H2 antihistamines, and other o...
Source: Indian Journal of Dermatology - February 23, 2023 Category: Dermatology Authors: Kiran Godse Anant Patil Abhishek De Nidhi Sharma Muralidhar Rajagopalan Bela Shah Sushil Tahiliani Mukesh Girdhar Vijay Zawar Prabhakar Sangolli DS Krupa Shankar Sandipan Dhar Source Type: research
Atopic status and thyroid autoimmunity do not predict omalizumab response in severe CSU patients
Eur Ann Allergy Clin Immunol. 2023 Feb 14. doi: 10.23822/EurAnnACI.1764-1489.283. Online ahead of print.NO ABSTRACTPMID:36786337 | DOI:10.23822/EurAnnACI.1764-1489.283
Source: European Annals of Allergy and Clinical Immunology - February 14, 2023 Category: Allergy & Immunology Authors: S Asero Source Type: research
